Experts in multiple myeloma discuss third-line and subsequent options for treating multiple myeloma, and BCMA-targeted approaches presented at the ASH 2020 Virtual Meeting.

Data from the following presentations are discussed:

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. (Madduri, ASH 2020 Abstract 177)

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. (Alsina, ASH 2020 Abstract130)

Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma. (Mailankody, ASH 2020 Abstract129)

Videos

Third and Subsequent Line Options for Multiple Myeloma

Important considerations regarding the sequencing of IMid–versus–PI-based approaches for relapsed/refractory multiple myeloma based on updates presented at the ASH 2020 Virtual Meeting.

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 CANDOR study. (Dimopoulos, ASH 2020 Abstract 2325)

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 CANDOR Study in Patients With Early or Late Relapse. (Weisel, ASH 2020 Abstract 2287)

Evaluation of Minimal Residual Disease (MRD) Negativity in Patients With Relapsed or Refractory Multiple Myeloma Treated in the CANDOR Study. (Landgren, ASH 2020 Abstract 2282)

Isatuxumab Plus Carfilzomib and Dexamethasone vs Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma (IKEMA): Interim Analysis of a Phase 3, Randomized, Open-label Study. (Moreau, ASH 2020 Abstract 2316)

APOLLO: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). (Dimopoulos, ASH 2020 Abstract 412)

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma. (Sebag, ASH 2020, Abstract 413)

Updates in Relapsed/Refractory Myeloma

Insight regarding updates in the frontline setting for patients with multiple myeloma, including quad versus triplet regimens, the use of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab, and transplant in newly diagnosed multiple myeloma.

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy. (Kaufman, ASH 2020, Abstract549)

Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. (Landgren, ASH 2020 Abstract 3204)

Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. (Perrot, ASH 2020 Abstract 143)

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial. (Gay, ASH 2020 Abstract141)

Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

Articles

Third and Subsequent Line Options for Multiple Myeloma

Updates in Relapsed/Refractory Myeloma

Updates in Multiple Myeloma in the Frontline Setting